Ulland Investment Advisors LLC Has $964,000 Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Ulland Investment Advisors LLC boosted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,780 shares of the medical equipment provider’s stock after purchasing an additional 374 shares during the period. Ulland Investment Advisors LLC’s holdings in Lantheus were worth $964,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Creative Planning boosted its stake in shares of Lantheus by 5.4% in the 3rd quarter. Creative Planning now owns 24,988 shares of the medical equipment provider’s stock valued at $2,742,000 after purchasing an additional 1,274 shares in the last quarter. Kathleen S. Wright Associates Inc. acquired a new stake in Lantheus in the third quarter valued at approximately $51,000. Procyon Advisors LLC grew its stake in shares of Lantheus by 16.0% during the third quarter. Procyon Advisors LLC now owns 3,252 shares of the medical equipment provider’s stock worth $357,000 after buying an additional 449 shares during the last quarter. Shaker Investments LLC OH increased its holdings in shares of Lantheus by 60.5% during the third quarter. Shaker Investments LLC OH now owns 44,803 shares of the medical equipment provider’s stock worth $4,917,000 after buying an additional 16,886 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in shares of Lantheus by 57.1% in the 3rd quarter. Exchange Traded Concepts LLC now owns 1,266 shares of the medical equipment provider’s stock valued at $139,000 after acquiring an additional 460 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Trading Up 0.7 %

Shares of LNTH stock traded up $0.74 during mid-day trading on Tuesday, hitting $111.46. The company’s stock had a trading volume of 100,201 shares, compared to its average volume of 976,409. The company has a market cap of $7.73 billion, a PE ratio of 16.90 and a beta of 0.50. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The company’s fifty day simple moving average is $104.44 and its 200-day simple moving average is $89.85. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.40 earnings per share. As a group, equities research analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now owns 98,980 shares in the company, valued at approximately $9,540,682.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now directly owns 98,980 shares of the company’s stock, valued at $9,540,682.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gerard Ber sold 15,500 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,981 shares of company stock worth $2,689,156. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Truist Financial reduced their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. B. Riley upped their price objective on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Leerink Partners lifted their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Redburn Atlantic initiated coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target for the company. Finally, JMP Securities cut their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and an average price target of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.